二甲双胍单药治疗2型糖尿病时加用胰岛素与磺脲类对肾功能下降预防效果的比较
回顾性队列研究纳入2001至2008年接受二甲双胍单药治疗的退伍军人,按1:4倾向评分匹配分为加用胰岛素组(1989例)和加用磺脲类组(7956例),随访至2011年9月。加用胰岛素组主要复合终点(eGFR持续下降≥35%或ESRD)发生率31/1000人年 vs 磺脲类组26/1000人年(校正HR 1.27,95%CI 0.99-1.63),次要终点(GFR事件、ESRD或死亡)64 vs 49/1000人年(校正HR 1.33,95%CI 1.11-1.59)。基线eGFR与干预对两终点均无显著交互作用(P=0.39和P=0.12)。
要点
- 加用胰岛素与磺脲类相比,主要肾脏复合终点无显著差异(校正HR 1.27,95%CI 0.99-1.63)。
- 加用胰岛素组次要复合终点(含死亡)发生率更高(校正HR 1.33,95%CI 1.11-1.59)。
- 基线eGFR与干预对主要和次要终点均无显著交互作用(P=0.39和P=0.12)。
核心结论
- 在二甲双胍单药治疗需要强化治疗的患者中,加用胰岛素与加用磺脲类相比,肾脏结局发生率无显著差异但有升高趋势(校正HR 1.27,95%CI 0.99-1.63)。
- 加用胰岛素与加用磺脲类相比,包含死亡的复合终点发生率显著升高(校正HR 1.33,95%CI 1.11-1.59)。
- 基线eGFR未修饰上述风险(交互作用P=0.39和P=0.12)。
研究设计与样本
- 回顾性队列研究,纳入2001至2008年接受二甲双胍单药治疗的退伍军人,随访至2011年9月。
- 采用1:4倾向评分匹配,加用胰岛素组1989例,加用磺脲类组7956例。
- 主要复合终点为eGFR较基线持续下降≥35%(GFR事件)或诊断为ESRD;次要终点为GFR事件、ESRD或死亡。
- 采用边际结构模型校正时间依赖协变量,主要分析要求持续使用强化方案。
主要发现
- 中位年龄60岁(四分位距54-67),中位血红蛋白A1c 8.1%(四分位距7.1%-9.9%),中位肌酐1.0 mg/dl(四分位距0.9-1.1)。
- 主要复合终点发生率:加用胰岛素组31/1000人年 vs 加用磺脲类组26/1000人年(校正HR 1.27,95%CI 0.99-1.63)。
- 次要复合终点发生率:加用胰岛素组64/1000人年 vs 加用磺脲类组49/1000人年(校正HR 1.33,95%CI 1.11-1.59)。
- 基线eGFR与干预对主要终点的交互作用无统计学意义(P=0.39),对次要终点的交互作用无统计学意义(P=0.12)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Diabetes is the leading cause of ESRD. Glucose control improves kidney outcomes. Most patients eventually require treatment intensification with second-line medications; however, the differential effects of those therapies on kidney function are unknown. DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: We studied a retrospective cohort of veterans on metformin monotherapy from 2001 to 2008 who added either insulin or sulfonylurea and were followed through September of 2011. We used propensity score matching 1:4 for those who intensified with insulin versus sulfonylurea, respectively. The primary composite outcome was persistent decline in eGFR≥35% from baseline (GFR event) or a diagnosis of ESRD. The secondary outcome was a GFR event, ESRD, or death. Outcome risks were compared using marginal structural models to account for time-varying covariates. The primary analysis required persistence with the intensified regimen. An effect modification of baseline eGFR and the intervention on both outcomes was evaluated. RESULTS: There were 1989 patients on metformin and insulin and 7956 patients on metformin and sulfonylurea. Median patient age was 60 years old (interquartile range, 54-67), median hemoglobin A1c was 8.1% (interquartile range, 7.1%-9.9%), and median creatinine was 1.0 mg/dl (interquartile range, 0.9-1.1). The rate of GFR event or ESRD (primary outcome) was 31 versus 26 per 1000 person-years for those who added insulin versus sulfonylureas, respectively (adjusted hazard ratio, 1.27; 95% confidence interval, 0.99 to 1.63). The rate of GFR event, ESRD, or death was 64 versus 49 per 1000 person-years, respectively (adjusted hazard ratio, 1.33; 95% confidence interval, 1.11 to 1.59). Tests for a therapy by baseline eGFR interaction for both the primary and secondary outcomes were not significant (P=0.39 and P=0.12, respectively). CONCLUSIONS: Among patients who intensified metformin monotherapy, the addition of insulin compared with a sulfonylurea was not associated with a higher rate of kidney outcomes but was associated with a higher rate of the composite outcome that included death. These risks were not modified by baseline eGFR.
引用
- Hung AM, Roumie CL, Greevy RA, et al. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline. Clin J Am Soc Nephrol. 2016. PMID: 27827311. doi:10.2215/CJN.02630316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。